The following products have been found matching your search "K04368": 199

MEK kinases are central components of diverse intracellular signaling pathways. MEK1 and MEK2 specifically act downstream of growth factor receptors and the proto-oncogenes Ras and Raf to activate ERK1 and ERK2, often leading to an increase in cell proliferation. AZD 6244 is a potent, highly selective inhibitor of...

U-0126 is a MEK inhibitor with IC50 values of 72 nM and 58 nM for MEK1 and MEK2, respectively. It is noncompetitive with respect adenosine triphosphate (ATP) and its phosphorylation target ERK and it shows little to no inhibition against a number of other kinases including PKC, Ab1, Raf, MEKK, ERK, JNK, MKK-3,...

PD 98059 is a noncompetitive inhibitor of the MAPK pathway. It prevents the activation of MEK by Raf or MEK kinase (a MAPKKK) with an IC50 value of 2-7 µM but does not inhibit Raf-activated MAPKK1. It inhibits Raf activation of MAPKK2 with an IC50 value of 50 µM. PD 98059 also phosphorylates and activates...

The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. PD 0325901 is a potent MEK inhibitor that suppresses phosphorylation of ERK in mouse colon 26 tumors with an IC50 value of 0.33 nM. Suppression of ERK activation...

The dual specificity mitogen-activated protein kinase kinases (MEK) isoforms MEK1 and MEK2 function in a RAS/RAF/MEK/ERK signaling pathway to control cell growth, survival, and differentiation. Trametinib is a potent inhibitor of both MEK 1 and 2 that works in an ATP-noncompetitive fashion (IC50s = 0.7 and 0.9 nM,...

Cell permeable, specific p38 MAP kinase inhibitor, Binds to the ATP binding site of p38 MAP kinase, T cell proliferation inhibitor, IL-2 production inhibitor, SAPK/JNK inhibitor, COX-1 and -2 inhibitor, Raf-1 activator, Apoptosis enhancer, Antiproliferative, PDK1 inhibitor, Anti-inflammatory, Review.

Soluble in DMSO. Cobimetinib demonstrated a sustained tumor pharmacodynamic response due to longer residence times in tumor tissue than in plasma in mice. Following single doses, cobimetinib inhibited pERK in tumors with IC50 values of 780 nM in WM-266-4 and 520 nM in A375 xenograft mice. Following multiple doses,...

Soluble in DMSO. This research compound is the DMSO solvate form of trametinib. Trametinib is a selective MEK inhibitor. Trametinib inhibited MEK1/2 kinase activity, prevented Raf-dependent MEK phosphorylation, and produced prolonged p-ERK1/2 inhibition. It blocked the cell growth potently in most tumor lines with...

Binimetinib is an orally bioavailable inhibitor of MEK1/2 (IC50 = 12 nM). It has been found to inhibit ERK phosphorylation in various cancer cell lines (IC50s > 5 nM). This compound is efficacious in several xenograft tumor models in mice, including those bearing K-Ras or B-RAF mutations, and has been characterized...

Trametinib-13C-d3 is intended for use as an internal standard for the quantification of trametinib (Cay-16292) by GC- or LC-MS. Trametinib is an inhibitor of MEK1 and -2. It inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM,...

Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. GSK1120212 (JTP-74057, trametinib) is a highly specific and potent MEK1 and MEK2 inhibitor with IC(50) values of 0.92nM and 1.8nM respectively. Target: MEK1 - MEK2 , Kinase Group: STE , Substrate: Serine-Threonine

The dual specific threonine/tyrosine kinase, map kinase kinase (MEK), is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. CI-1040 is a benzhydroxamate compound that potently inhibits MEK in an in vitro mitogen-activated protein kinase cascade assay with an IC50...